leisure time -WSS

leisure time

author：hotspot 2025-10-04 11:07:32 - browse：24453

A cloud with a medical folder on the top of an illustration is connected to other medical vectors such as a doctor on a phone screen, a health watch, and a brain chip — coverage from STAT — Adobe

Federal health technology regulators on Wednesday finalized new rules to force software vendors to disclose how artificial intelligence tools are trained, developed, and tested — a move to protect patients against biased and harmful decisions about their care.

The rules are aimed at placing guardrails around a new generation of AI models gaining rapid adoption in hospitals and clinics around the country. These tools are meant to help predict health risks and emergent medical problems, but little is publicly known about their effectiveness, reliability, or fairness.

Starting in 2025, electronic health record vendors who develop or supply these tools, which increasingly use a type of AI known as machine learning, will be required to disclose more technical information to clinical users about their performance and testing, as well as the steps taken to manage potential risks.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Abortion pill case raises question: who can sue the FDA?

WSS

Readout LOUD podcast, live from the STAT Breakthrough Summit East

States should stop sabotaging methadone treatment reform

6 surprising facts about sugar

Erich Jarvis studies song birds to learn about human stuttering

Chinese researcher claims birth of first gene

Why the world’s most expensive drug might be worth the price

explore

leisure time

entertainment

Activists slam private health insurers over coverage restrictions

6 surprising facts about sugar

Malaria cases in Florida and Texas: Here’s what you need to know

Erich Jarvis studies song birds to learn about human stuttering

Psychedelics group wrestles with new pharma identity

Merck drug for rare lung condition set for approval in U.S.

Supreme Court strikes down use of affirmative action

States should stop sabotaging methadone treatment reform

The cancer drug shortage isn’t new — and neither are the solutions

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

focus

Covid vaccine financial winners and losers, from Pfizer to Novavax

Study says nonprofit hospitals fall short in charity care spending

Donor acceptance rates hint at racial, gender bias in heart transplants: study

FDA's naming rule on biosimilars has undermined competition

Readout LOUD podcast, live from the STAT Breakthrough Summit East

FDA's naming rule on biosimilars has undermined competition

hotspot

entertainment

leisure time

Wikipedia